Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020989916> ?p ?o ?g. }
- W2020989916 endingPage "948.e3" @default.
- W2020989916 startingPage "940" @default.
- W2020989916 abstract "Behçet's disease is a chronic, relapsing inflammatory disease that can involve the mouth, skin, eyes, genitals, and intestines. Active intestinal Behçet's disease can be complicated by gastrointestinal (GI) bleeding and perforation. We performed a multicenter, open-label, uncontrolled study to evaluate the efficacy and safety of adalimumab, a fully human monoclonal antibody against tumor necrosis factor α, in patients with intestinal Behçet's disease who were refractory to corticosteroid and/or immunomodulator therapies.The study was conducted at 12 sites in Japan, from November 2010 through October 2012. Twenty patients were given 160 mg adalimumab at the start of the study and 80 mg 2 weeks later, followed by 40 mg every other week for 52 weeks; for some patients, the dose was increased to 80 mg every other week. A composite efficacy index, combining GI symptom and endoscopic assessments, was used to evaluate efficacy. The primary efficacy end point was the percentage of patients with scores of 1 or lower for GI symptom and endoscopic assessments at week 24. Secondary end points included complete remission and resolution of non-GI Behçet's-related symptoms.Nine patients (45%) had GI symptom and endoscopic assessment scores of 1 or lower at week 24 of treatment, and 12 patients (60%) had these scores by week 52. Four patients (20%) achieved complete remission at weeks 24 and 52. Individual global GI symptom and endoscopic scores improved for most patients at weeks 24 and 52. Two thirds of patients with oral aphthous ulcers, skin symptoms, and genital ulcers, and 88% of patients with erythema nodosum had complete resolution of these conditions at week 52. A total of 9 of 13 patients (69%) taking steroids at baseline were able to taper (n = 1) or completely discontinue steroids (n = 8) during the study. No new safety signals were observed.Adalimumab is a potentially effective treatment for intestinal Behçet's disease in Japanese patients who are refractory to conventional treatments. ClinicalTrials.gov number: NCT01243671." @default.
- W2020989916 created "2016-06-24" @default.
- W2020989916 creator A5000248643 @default.
- W2020989916 creator A5014227547 @default.
- W2020989916 creator A5018825142 @default.
- W2020989916 creator A5018853775 @default.
- W2020989916 creator A5026205612 @default.
- W2020989916 creator A5031542442 @default.
- W2020989916 creator A5037994084 @default.
- W2020989916 creator A5038779972 @default.
- W2020989916 creator A5045329864 @default.
- W2020989916 creator A5048983541 @default.
- W2020989916 creator A5056822373 @default.
- W2020989916 creator A5057448803 @default.
- W2020989916 creator A5058783597 @default.
- W2020989916 creator A5062739693 @default.
- W2020989916 creator A5065128587 @default.
- W2020989916 creator A5069356522 @default.
- W2020989916 creator A5076408477 @default.
- W2020989916 creator A5081127025 @default.
- W2020989916 date "2015-05-01" @default.
- W2020989916 modified "2023-10-14" @default.
- W2020989916 title "Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease" @default.
- W2020989916 cites W1970915413 @default.
- W2020989916 cites W1991810959 @default.
- W2020989916 cites W2002143329 @default.
- W2020989916 cites W2013993043 @default.
- W2020989916 cites W2019139983 @default.
- W2020989916 cites W2022970811 @default.
- W2020989916 cites W2030136625 @default.
- W2020989916 cites W2044240158 @default.
- W2020989916 cites W2057915378 @default.
- W2020989916 cites W2060886633 @default.
- W2020989916 cites W2077793881 @default.
- W2020989916 cites W2084586997 @default.
- W2020989916 cites W2086050457 @default.
- W2020989916 cites W2091666083 @default.
- W2020989916 cites W2092863985 @default.
- W2020989916 cites W2097235170 @default.
- W2020989916 cites W2109736067 @default.
- W2020989916 cites W2110825013 @default.
- W2020989916 cites W2133633410 @default.
- W2020989916 cites W2134293291 @default.
- W2020989916 cites W2142903054 @default.
- W2020989916 cites W2149839018 @default.
- W2020989916 cites W2152026434 @default.
- W2020989916 cites W2328281435 @default.
- W2020989916 cites W4236479214 @default.
- W2020989916 cites W4244113530 @default.
- W2020989916 doi "https://doi.org/10.1016/j.cgh.2014.08.042" @default.
- W2020989916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25245624" @default.
- W2020989916 hasPublicationYear "2015" @default.
- W2020989916 type Work @default.
- W2020989916 sameAs 2020989916 @default.
- W2020989916 citedByCount "81" @default.
- W2020989916 countsByYear W20209899162015 @default.
- W2020989916 countsByYear W20209899162016 @default.
- W2020989916 countsByYear W20209899162017 @default.
- W2020989916 countsByYear W20209899162018 @default.
- W2020989916 countsByYear W20209899162019 @default.
- W2020989916 countsByYear W20209899162020 @default.
- W2020989916 countsByYear W20209899162021 @default.
- W2020989916 countsByYear W20209899162022 @default.
- W2020989916 countsByYear W20209899162023 @default.
- W2020989916 crossrefType "journal-article" @default.
- W2020989916 hasAuthorship W2020989916A5000248643 @default.
- W2020989916 hasAuthorship W2020989916A5014227547 @default.
- W2020989916 hasAuthorship W2020989916A5018825142 @default.
- W2020989916 hasAuthorship W2020989916A5018853775 @default.
- W2020989916 hasAuthorship W2020989916A5026205612 @default.
- W2020989916 hasAuthorship W2020989916A5031542442 @default.
- W2020989916 hasAuthorship W2020989916A5037994084 @default.
- W2020989916 hasAuthorship W2020989916A5038779972 @default.
- W2020989916 hasAuthorship W2020989916A5045329864 @default.
- W2020989916 hasAuthorship W2020989916A5048983541 @default.
- W2020989916 hasAuthorship W2020989916A5056822373 @default.
- W2020989916 hasAuthorship W2020989916A5057448803 @default.
- W2020989916 hasAuthorship W2020989916A5058783597 @default.
- W2020989916 hasAuthorship W2020989916A5062739693 @default.
- W2020989916 hasAuthorship W2020989916A5065128587 @default.
- W2020989916 hasAuthorship W2020989916A5069356522 @default.
- W2020989916 hasAuthorship W2020989916A5076408477 @default.
- W2020989916 hasAuthorship W2020989916A5081127025 @default.
- W2020989916 hasBestOaLocation W20209899161 @default.
- W2020989916 hasConcept C121332964 @default.
- W2020989916 hasConcept C126322002 @default.
- W2020989916 hasConcept C141071460 @default.
- W2020989916 hasConcept C142424586 @default.
- W2020989916 hasConcept C191897082 @default.
- W2020989916 hasConcept C192562407 @default.
- W2020989916 hasConcept C2778456384 @default.
- W2020989916 hasConcept C2778527123 @default.
- W2020989916 hasConcept C2779134260 @default.
- W2020989916 hasConcept C2780132546 @default.
- W2020989916 hasConcept C2780479503 @default.
- W2020989916 hasConcept C2781428731 @default.
- W2020989916 hasConcept C71924100 @default.
- W2020989916 hasConcept C87355193 @default.